Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence.

IF 5.3 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Molecular Therapy Oncolytics Pub Date : 2022-06-07 eCollection Date: 2022-09-15 DOI:10.1016/j.omto.2022.06.004
Andrew B Satterlee, Denise E Dunn, Alain Valdivia, Daniel Malawsky, Andrew Buckley, Timothy Gershon, Scott Floyd, Shawn Hingtgen
{"title":"Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence.","authors":"Andrew B Satterlee,&nbsp;Denise E Dunn,&nbsp;Alain Valdivia,&nbsp;Daniel Malawsky,&nbsp;Andrew Buckley,&nbsp;Timothy Gershon,&nbsp;Scott Floyd,&nbsp;Shawn Hingtgen","doi":"10.1016/j.omto.2022.06.004","DOIUrl":null,"url":null,"abstract":"<p><p>Genetically engineered neural stem cells (NSCs) are a promising therapy for the highly aggressive brain cancer glioblastoma (GBM); however, treatment durability remains a major challenge. We sought to define the events that contribute to dynamic adaptation of GBM during treatment with human skin-derived induced NSCs releasing the pro-apoptotic agent TRAIL (iNSC-TRAIL) and develop strategies that convert initial tumor kill into sustained GBM suppression. <i>In vivo</i> and <i>ex vivo</i> analysis before, during, and after treatment revealed significant shifts in tumor transcriptome and spatial distribution as the tumors adapted to treatment. To address this, we designed iNSC delivery strategies that increased spatiotemporal TRAIL coverage and significantly decreased GBM volume throughout the brain, reducing tumor burden 100-fold as quantified in live <i>ex vivo</i> brain slices. The varying impact of different strategies on treatment durability and median survival of both solid and invasive tumors provides important guidance for optimizing iNSC therapy.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"26 ","pages":"49-62"},"PeriodicalIF":5.3000,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/99/main.PMC9217992.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2022.06.004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/15 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

Abstract

Genetically engineered neural stem cells (NSCs) are a promising therapy for the highly aggressive brain cancer glioblastoma (GBM); however, treatment durability remains a major challenge. We sought to define the events that contribute to dynamic adaptation of GBM during treatment with human skin-derived induced NSCs releasing the pro-apoptotic agent TRAIL (iNSC-TRAIL) and develop strategies that convert initial tumor kill into sustained GBM suppression. In vivo and ex vivo analysis before, during, and after treatment revealed significant shifts in tumor transcriptome and spatial distribution as the tumors adapted to treatment. To address this, we designed iNSC delivery strategies that increased spatiotemporal TRAIL coverage and significantly decreased GBM volume throughout the brain, reducing tumor burden 100-fold as quantified in live ex vivo brain slices. The varying impact of different strategies on treatment durability and median survival of both solid and invasive tumors provides important guidance for optimizing iNSC therapy.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
诱导神经干细胞治疗克服晚期胶质母细胞瘤复发的时空分析。
基因工程神经干细胞(NSCs)是治疗高度侵袭性脑癌症胶质母细胞瘤(GBM)的一种有前景的治疗方法;然而,治疗的持久性仍然是一个主要挑战。我们试图定义在用释放促凋亡剂TRAIL(iNSC TRAIL)的人类皮肤诱导的NSCs治疗期间有助于GBM动态适应的事件,并开发将初始肿瘤杀伤转化为持续GBM抑制的策略。治疗前、治疗中和治疗后的体内和离体分析显示,随着肿瘤适应治疗,肿瘤转录组和空间分布发生了显著变化。为了解决这一问题,我们设计了iNSC递送策略,该策略增加了时空TRAIL的覆盖率,并显著降低了整个大脑的GBM体积,将肿瘤负担降低了100倍,这在活体离体脑切片中进行了量化。不同策略对实体瘤和侵袭性肿瘤的治疗持久性和中位生存率的不同影响为优化iNSC治疗提供了重要指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics Medicine-Oncology
CiteScore
10.90
自引率
3.50%
发文量
152
审稿时长
6 weeks
期刊介绍: Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
期刊最新文献
Targeting mesothelin in cancer New advances in cancer therapy targeting TGF-β signaling pathways miR-146a: Overcoming coldness in ovarian cancer Thank you to our 2023 reviewers Gaining insights into virotherapy with canine models
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1